Dorzolamide Hydrochloride and Zonegran

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Talk to your doctor before using dorzolamide ophthalmic together with zonisamide. After dorzolamide ophthalmic is instilled into the eye, the medication can be absorbed into the bloodstream and cause some of the same effects as zonisamide. This may increase the risk and/or severity of side effects like drowsiness, dizziness, numbness, tingling, ringing in the ears, loss of appetite, nausea, vomiting, diarrhea, kidney stones, fever, and heat stroke. You should drink plenty of fluids while being treated with zonisamide, especially during exercise or prolonged exposure to warm temperatures. Let your doctor know if you experience sudden back pain, abdominal pain, blood in the urine, painful urination, numbness or tingling in the hands and feet, decreased sweating, or a rise in body temperature. Avoid driving or operating hazardous machinery until you know how the medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Following ophthalmic administration, brinzolamide and dorzolamide are systemically absorbed and may have additive pharmacologic effects with other, systemically administered carbonic anhydrase inhibitors. Specific data are not available regarding coadministration with topiramate or zonisamide, which are anticonvulsants with some carbonic anhydrase inhibiting activity. Theoretically, adverse effects such as drowsiness, paresthesia, tinnitus, electrolyte imbalance, metabolic acidosis, and gastrointestinal disturbances may be increased. Carbonic anhydrase inhibition can also promote kidney stone formation by reducing urinary citrate excretion and increasing urinary pH, and cause oligohidrosis or hyperthermia by altering electrolyte and fluid balance. Oligohidrosis and hyperthermia are sometimes associated with serious sequelae but may be preventable by prompt recognition of symptoms and appropriate treatment.

MANAGEMENT: The concomitant use of ocular and systemic carbonic anhydrase inhibitors is not recommended. Patients treated with topiramate or zonisamide should be advised to increase fluid intake to enhance urinary output, which lowers the concentration of substances involved in stone formation. Patients should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended. Patients should contact their doctor immediately if they develop signs or symptoms of kidney stones such as sudden back pain, abdominal pain, blood in the urine and/or painful urination, or if they experience a rise in body temperature or decreased sweating.

Dorzolamide Hydrochloride

Generic Name: dorzolamide ophthalmic

Brand name: Trusopt

Synonyms: Dorzolamide ophthalmic, Dorzolamide

What is Dorzolamide Hydrochloride?

Zonegran

Generic Name: zonisamide

Brand name: Zonegran

Synonyms: n.a.

What is Zonegran?